Dayvigo (generic name brexpiprazole) is a prescription antipsychotic that is primarily used to treat major depressive disorder (MDD) when combined with an antidepressant. It’s part of the dopamine D₂/5‑HT₁A receptor partial agonist class, which is sometimes called a “second‑generation” or atypical antipsychotic.
Key Facts
| Feature |
Details |
| Brand name |
Dayvigo |
| Generic |
Brexpiprazole |
| FDA approved |
2019 for MDD + antidepressant (also approved for schizophrenia in 2015) |
| Form |
Oral tablet, 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg |
| Typical starting dose |
1 mg once daily (often with a 1‑week titration to 2 mg) |
| Maximum recommended dose |
8 mg once daily |
| Commonly prescribed |
With an antidepressant for treatment‑resistant or moderate‑to‑severe MDD |
How It Works
Brexpiprazole binds to several neurotransmitter receptors:
- Partial agonist at dopamine D₂ → balances dopamine activity.
- Partial agonist at serotonin 5‑HT₁A → modulates serotonin signaling.
- Antagonist at serotonin 5‑HT₂A and 5‑HT₂C → reduces some side‑effect risks.
- Antagonist at α₂C‑adrenergic → may improve cognition.
By modulating both dopamine and serotonin systems, it helps lift mood and reduce depressive symptoms.
Typical Use‑Case
- Major depressive disorder: Usually added to an ongoing SSRI, SNRI, or TCA.
- Schizophrenia (older indication): Used as monotherapy or adjunct.
Patients with inadequate response to a single antidepressant often benefit from the addition of Dayvigo.
Common Side Effects
| Category |
Examples |
| Central nervous system |
Akathisia (restlessness), insomnia, dizziness, headache, agitation |
| Metabolic |
Weight gain, increased appetite, mild elevation of blood sugar (rare) |
| Other |
Nausea, constipation, orthostatic hypotension (rare) |
Side‑effect profile is generally milder than older antipsychotics, but akathisia is the most frequent complaint.
What to Watch For
| Issue |
What to do |
| Akathisia |
May be managed with beta‑blockers (e.g., propranolol), anticholinergics, or dose adjustment. |
| Weight gain |
Monitor weight, encourage diet/exercise. |
| Orthostatic hypotension |
Check blood pressure especially after dose changes. |
| QT prolongation |
Rare but check ECG in patients with cardiac risk factors or on QT‑prolonging meds. |
| Interaction with other drugs |
Many antidepressants or MAOIs can increase risk of serotonin syndrome; check drug lists. |
| Pregnancy & breastfeeding |
Limited data – talk to your clinician. |
Drug‑Drug Interactions
| Interaction |
Impact |
What to do |
| SSRIs / SNRIs |
↑ risk of serotonin syndrome |
Monitor closely, consider dose titration. |
| CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) |
↑ brexpiprazole levels |
Lower dose or alternative antidepressant. |
| CYP3A4 inhibitors/inducers |
Alter metabolism |
Adjust dose accordingly. |
| Other antipsychotics |
Additive side‑effects (e.g., akathisia, weight gain) |
Use cautiously. |
Always tell your prescriber about all medications, supplements, and herbal products.
Common Patient Questions
Q: Can I take Dayvigo with an SSRI?
A: Yes – that’s the standard combination for MDD. The usual approach is to start the antidepressant first, then add Dayvigo at a low dose after a week or so of stable antidepressant therapy. Your clinician will monitor for side effects and response.
Q: Is it safe for me to drink alcohol while taking Dayvigo?
A: Alcohol may increase sedation and dizziness. It can also exacerbate akathisia. It’s best to limit alcohol intake and discuss with your prescriber.
Q: How long before I see improvement?
A: Most patients notice an improvement in mood and energy levels within 2–4 weeks, but full benefits can take 6–8 weeks. Consistency is key.
Q: What happens if I miss a dose?
A: Skip the missed dose, take the next one at its regular time, and do not double‑dose. If you miss several doses, contact your prescriber.
When to Call a Professional
- Sudden or severe dizziness, fainting, or feeling faint.
- Unusual swelling of ankles, legs, or face.
- Symptoms of serotonin syndrome: agitation, confusion, rapid heart rate, shivering, sweating, tremor.
- Persistent nausea, vomiting, or severe constipation.
- Any new or worsening psychiatric symptoms, especially suicidal thoughts.
Bottom Line
Dayvigo is a newer, well‑tolerated option for people who haven’t found full relief with an antidepressant alone. It offers a more balanced approach to neurotransmitter modulation compared with older antipsychotics, with a side‑effect profile that is generally easier to manage—though akathisia and mild metabolic changes remain common. As with any medication, close communication with your healthcare provider, regular monitoring, and a good medication review can help you get the most benefit with the least risk.